Alert
Close

Think you know AARP? What you don't know about us may surprise you. Discover all the 'Real Possibilities'

Donate

Be part of the solution.

Help AARP Foundation win back opportunity for struggling Americans 50 and over.

Charity Rating

AARP Foundation earns high rating for accountability from a leading charity evaluator. Read

 

about
Foundation

AARP Foundation is dedicated to serving vulnerable people 50+ by creating solutions that help them secure the essentials and achieve their best life. Read

 

Foundation Overview
Governance
Executive Leadership
Financial Information
Diversity Practices

Sanofi-Aventis v. FDA

Federal Court Denies Injunction Against FDA Approval of Biologic-like Generic Drug

The Ruling

The U.S. District Court for the District of Columbia was unpersuaded by Sanofi's argument that an injunction is needed, ruling in Sanofi-Aventis v. FDA et al. that the tests for an injunction require a very high showing that Sanofi did not meet.

Among other things, the court found that the public would be harmed by a court-ordered delay in the distribution of a generic drug that is approximately 30 percent to 35 percent cheaper than Lovenox. Citing AARP's amicus brief, the court concluded that Sanofi had failed to establish that the public interest favors interim injunctive relief.

As noted in The Wall Street Journal, "The Lovenox case is being closely followed by the drug industry because it hinges largely on the Food and Drug Administration's authority to set special standards for approving certain complex protein-based drugs. The decision could affect future FDA methods for approving generic biologic drugs."

Search Legal Advocacy

Find
Legal Cases

Find the most recent cases in which AFL has advocated in courts nationwide for the rights of older persons, and filed AARP’s amicus curiae (“friend of the court”) briefs that help courts decide precedent-setting cases.

Make a Difference. Donate.

Make a Difference — support programs that help vulnerable seniors who are struggling to make ends meet.